Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3437943 in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Have Type 2 Diabetes (T2D)~* Have an HbA1c value at screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or with a stable dose of metformin (either immediate release or extended release, 1000 milligram (mg)/day and not more than the locally approved dose) for at least 3 months prior to screening.~Exclusion Criteria:~* Have type 1 diabetes mellitus (T1DM)~* Have ketoacidosis~* Have retinopathy, maculopathy~* Have history of pancreatitis~* Have obesity induced by other endocrine disorders~* Have uncontrolled hypertension~* Have acute or chronic hepatitis~* Have chronic kidney disease~* Have an autoimmune abnormality for example, lupus or rheumatoid arthritis~* Have an active or untreated malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 0.5 milligrams (mg) LY3437943 (Type: EXPERIMENTAL): Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).
- 4 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
- 4 mg LY3437943 (4 mg) (Type: EXPERIMENTAL): Participants received 4 mg LY3437943 administered as SC injection QW.
- 8 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
- 8 mg LY3437943 (4 mg) (Type: EXPERIMENTAL): Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.
- 12 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.
- 1.5 mg Dulaglutide (Type: ACTIVE_COMPARATOR): Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered as SC injection QW.

Based on this trial design, predict the completion outcome and termination type (if applicable).